US5622867A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prolonged preservation of blood platelets
Assignee: LifeCell Corp
•
Filing: 1994-10-19
•
Granted: 1997-04-22
•
Expires: 2014-10-19
Abstract
Abstract This invention provides a method for prolonging the preservation of human blood platelets at reduced temperatures. The method uses an inhibitor system that enables blood platelets to maintain their discoid shape and retain their functional integrity during storage. This is accomplished by interrupting normal platelet function during storage, so as to help keep platelets from activating and losing their shape. Before using the platelets in a transfusion, they are returned to their normal functional level by washing the inhibitor system away from the platelets.
Inventors
- 👤 Stephen A. Livesey
- 👤 Jerome Connor
- 👤 Laura M. Currie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 03:59
CPC Classifications
A; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/19; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/108331; Y10T436/25; Y10T436/2525
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
101 words
An inhibitor system effective to prolong the in vitro presentation of human platelets at temperatures of 8° C. and below, said system capable of inhibiting platelet activity during storage, but enabling platelet activity to resume after the inhibitor system is removed from the platelets, comprising: a plasma phase containing amiloride, sodium nitroprusside, adenosine, dipyridamole, quinacrine, ticlopidine and heparin in amounts effective to prolong storage time of bioactive platelets, said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway.
Claim 2
Dependent Claim
101 words
An inhibitor system effective to prolong the in vitro presentation of human platelets at temperatures of 8° C. and below, said system capable of inhibiting platelet activity during storage, but enabling platelet activity to resume after the inhibitor system is removed from the platelets, comprising: a plasma phase containing amiloride, sodium nitroprusside, adenosine, dipyridamole, quinacrine, ticlopidine and heparin in amounts effective to prolong storage time of bioactive platelets, said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway.
Claim 3
Dependent Claim
121 words
A platelet storage composition effective to prolong the in vitro preservation of platelets at temperatures of 8° C. and below comprising a plasma excipient for platelet storage which includes between about 0.1 mM and 10 mM amiloride, between about 2.5 uM and 250 uM sodium nitroprusside, between about 10 uM and 1 mM adenosine, between about 10 nM and 1 uM quinacrine, between about 2 uM and 200 uM dipyridamole; between about 0.5 mM and 5 mM ticlopidine, and between about 5 units/ml to about 200 units/ml heparin, said plasma excipient being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway.
Claim 4
Dependent Claim
121 words
A platelet storage composition effective to prolong the in vitro preservation of platelets at temperatures of 8° C. and below comprising a plasma excipient for platelet storage which includes between about 0.1 mM and 10 mM amiloride, between about 2.5 uM and 250 uM sodium nitroprusside, between about 10 uM and 1 mM adenosine, between about 10 nM and 1 uM quinacrine, between about 2 uM and 200 uM dipyridamole; between about 0.5 mM and 5 mM ticlopidine, and between about 5 units/ml to about 200 units/ml heparin, said plasma excipient being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway.
Claim 5
Dependent Claim
17 words
The composition of claim 2 further comprising between about 0.5% to about 10% of a cryopreservation agent.
Claim 6
Dependent Claim
17 words
The composition of claim 3 wherein said cryopreservation agent is between about 0.5% and 6% dimethyl sulfoxide.
Claim 7
Dependent Claim
19 words
The composition of claim 3 wherein said cryopreservation agent is dimethyl sulfoxide present at a concentration of about 2%.
Claim 8
Dependent Claim
14 words
The composition of claim 1 wherein said amiloride concentration is about 1 mM amiloride.
Claim 9
Dependent Claim
14 words
The composition of claim 1 wherein said sodium nitroprusside concentration is about 25 uM.
Claim 10
Dependent Claim
13 words
The composition of claim 1 wherein said adenosine concentration is about 0.1 mM.
Claim 11
Dependent Claim
13 words
The composition of claim 1 wherein said quinacrine concentration is about 0.1 uM.
Claim 12
Dependent Claim
13 words
The composition of claim 1 wherein said dipyridamole concentration is about 20 uM.
Claim 13
Dependent Claim
13 words
The composition of claim 1 wherein said ticlopidine concentration is about 1.5 mM.
Claim 14
Dependent Claim
13 words
The composition of claim 1 wherein said heparin concentration is about 20 units/ml.
Claim 15
Independent Claim
105 words
A method for the prolonged in vitro storage of platelets at temperatures of 8° C. and below comprising the steps of: adding an inhibitor system capable of inhibiting platelet activity during storage, but enabling platelet activity to resume after the inhibitor system is removed from the platelets, comprising a plasma phase containing amiloride, sodium nitroprusside, adenosine, quinacrine, dipyridamole, ticlopidine, and heparin, said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; mixing said inhibitor system with a preparation of platelets; and refrigerating.
Claim 16
Independent Claim
105 words
A method for the prolonged in vitro storage of platelets at temperatures of 8° C. and below comprising the steps of: adding an inhibitor system capable of inhibiting platelet activity during storage, but enabling platelet activity to resume after the inhibitor system is removed from the platelets, comprising a plasma phase containing amiloride, sodium nitroprusside, adenosine, quinacrine, dipyridamole, ticlopidine, and heparin, said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; mixing said inhibitor system with a preparation of platelets; and refrigerating.
Claim 17
Dependent Claim
22 words
The method of claim 13 wherein said plasma inhibitor mixture further comprises between about 0.5% to about 10% of a cryopreservation agent.
Claim 18
Dependent Claim
17 words
The method of claim 14 wherein said cryopreservation agent is between about 0.5% and 6% dimethyl sulfoxide.
Claim 19
Dependent Claim
19 words
The method of claim 14 wherein said cryopreservation agent is dimethyl sulfoxide present at a concentration of about 6%.
Claim 20
Dependent Claim
18 words
The method of claim 13 wherein said amiloride is added in a concentration of from about 1 uM.
Claim 21
Dependent Claim
17 words
The method of claim 13 wherein said sodium nitroprusside is added in a concentration of 25 uM.
Claim 22
Dependent Claim
17 words
The method of claim 1 wherein said adenosine is added in a concentration of about 0.1 uM.
Claim 23
Dependent Claim
17 words
The method of claim 13 wherein said quinacrine is added in a concentration of about 0.1 uM.
Claim 24
Dependent Claim
17 words
The method of claim 13 wherein said dipyridamole is added in a concentration of about 20 uM.
Claim 25
Dependent Claim
17 words
The method of claim 13 wherein said ticlopidine is added in a concentration of about 1.5 mM.
Claim 26
Dependent Claim
17 words
The method of claim 13 wherein said heparin is added in a concentration of about 20 units/ml.
Claim 27
Independent Claim
126 words
A method for processing human blood comprising the steps of: a. drawing whole blood from a person via venipuncture; b. centrifuging the drawn blood to isolate platelet-rich plasma from the blood; c. centrifuging the platelet-rich plasma to form a platelet-poor plasma and a platelet pellet; d. adding to the platelet-poor plasma an inhibitor system comprising: amiloride; sodium nitroprusside; adenosine; quinacrine; dipyridamole; ticlopidine; heparin; said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; e. gently resuspending the platelet pellet in the platelet-poor plasma containing the inhibitor system; and f. storing resulting plasma containing the suspended pellet at a temperature of about 4° C.
Claim 28
Independent Claim
126 words
A method for processing human blood comprising the steps of: a. drawing whole blood from a person via venipuncture; b. centrifuging the drawn blood to isolate platelet-rich plasma from the blood; c. centrifuging the platelet-rich plasma to form a platelet-poor plasma and a platelet pellet; d. adding to the platelet-poor plasma an inhibitor system comprising: amiloride; sodium nitroprusside; adenosine; quinacrine; dipyridamole; ticlopidine; heparin; said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; e. gently resuspending the platelet pellet in the platelet-poor plasma containing the inhibitor system; and f. storing resulting plasma containing the suspended pellet at a temperature of about 4° C.
Claim 29
Independent Claim
131 words
A method for processing human blood comprising the steps of: a. drawing whole blood from a person via venipuncture; b. centrifuging the drawn blood to isolate platelet-rich plasma from the blood; c. centrifuging the platelet-rich plasma to form a platelet-poor plasma and a platelet pellet; d. adding to the platelet-poor plasma an inhibitor system comprising: amiloride; sodium nitroprusside; adenosine; quinacrine; dipyridamole; ticlopidine; heparin; dimethyl sulfoxide said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; e. gently resuspending the platelet pellet in the platelet-poor plasma containing the inhibitor system and a cryoprotector; and f. storing resulting plasma containing the suspended pellet at a temperature of about -80° C.
Claim 30
Independent Claim
131 words
A method for processing human blood comprising the steps of: a. drawing whole blood from a person via venipuncture; b. centrifuging the drawn blood to isolate platelet-rich plasma from the blood; c. centrifuging the platelet-rich plasma to form a platelet-poor plasma and a platelet pellet; d. adding to the platelet-poor plasma an inhibitor system comprising: amiloride; sodium nitroprusside; adenosine; quinacrine; dipyridamole; ticlopidine; heparin; dimethyl sulfoxide said inhibitor system being functionally effective to block the cyclic AMP pathway, the sodium channel, the cyclic GMP pathway, the cyclooxygenase pathway, the lipooxygenase pathway, the phospholipase pathway, and the membrane modification pathway; e. gently resuspending the platelet pellet in the platelet-poor plasma containing the inhibitor system and a cryoprotector; and f. storing resulting plasma containing the suspended pellet at a temperature of about -80° C.
References Cited (Backward Citations)
US4940581A
Cited
US5256559A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-04-21 | 2000-10-21 | 2001-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-04-21 | 2004-10-21 | 2005-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-04-21 | 2008-10-21 | 2009-04-22 | $7700.00 | Window Closed / Lapsed |